Aeglea BioTherapeutics (AGLE) Reports Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to. | April 12, 2023
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May. | April 12, 2023
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
News provided by
Share this article
Share this article
AUSTIN, Texas, April 1, 2021 /PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021.
Conference Details
Conference Date: Tuesday, April 6 and Thursday, April 8
Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea s president and chief executive officer and Michael C. Hanley, Aeglea s chief commercial officer
Conference Name: 20
Conference Date: Monday, April 12 through Thursday, April 15